Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review reports that 5-alpha reductase inhibitors, used to treat androgenic alopecia, may adversely affect sperm count, sexual function, and hormones in a subset of patients.

This source describes alopecia as a hair loss condition often driven by genetic and androgenic factors, with lifestyle elements like chemical treatments exacerbating the issue; Ayurvedic texts caution against scalp toxins and suggest traditional formulations for support.

This study discusses the impact of alopecia on individuals' appearance and psychological well-being, highlighting how factors like genetics and lifestyle influence hair loss, and explores traditional Ayurvedic approaches for managing and promoting hair regrowth.

5-alpha reductase inhibitors do not increase osteoporosis risk in women with certain hair loss conditions.

This study developed a bifunctional sodium hyaluronate microneedle patch incorporating glycyrrhizin-loaded dutasteride micelles and mesoporous polydopamine nanoparticles, which effectively inhibited DHT and reduced ROS in hair follicle cells, resulting in significantly accelerated hair growth in vitro and in vivo.

This review found that 5α-reductase inhibitors (such as finasteride and dutasteride) effectively reduce prostate size and stabilize hair loss but are associated with sexual dysfunction; they remain essential treatments for BPH and androgenic alopecia, requiring tailored risk-benefit assessments.

In this review, 5α-reductase inhibitors like finasteride and dutasteride were found to significantly reduce prostate volume and stabilize hair loss, but they also carry risks of sexual dysfunction, necessitating careful patient evaluation and monitoring.

This integrative literature review suggests that phytotherapeutic products, like Saw palmetto and Green tea, could serve as viable alternatives to current medications like finasteride for treating androgenetic alopecia, potentially offering fewer side effects.

This study reported that a novel cationic liposome formulation for delivering encapsulated Cas9 protein and sgRNA successfully decreased SRD5α2 mRNA expression by 29.7% in vitro, suggesting a potential alternative treatment option for conditions like prostate cancer and benign prostatic hyperplasia without current drug side effects.

This abstract does not provide any specific results or findings but describes male androgenic alopecia as a progressive and psychologically distressing hair-loss disorder involving hair follicle miniaturization.

In this paper, the authors detailed the role of 5-α-reductase in male androgenetic alopecia and discussed potential inhibitors like saw palmetto extracts, suggesting further investigation into their effects on hair follicles and associated biological processes.

This case report describes a unique instance where elevated prolactin levels from a pituitary adenoma were associated with hirsutism due to increased dihydrotestosterone, with treatment leading to normalization.

This review discusses the pharmacology of 5-alpha reductase inhibitors, their expanding clinical indications beyond benign prostatic hyperplasia, and notes unresolved claims about their potential role in SARS-CoV-2.

This study identified two potent 5α-reductase inhibitors from Tectona grandis leaves, and suggests that ethanol is a preferable solvent for extracting these compounds, which are potential ingredients for hair loss treatments.

This study found that finasteride treatment may decrease contraction of seminal vesicle tissue and alter some semen parameters in male rabbits.

This study reported that cognitive biopsy diagnosed prostate cancer in 44% of patients with at least one previous negative biopsy, with higher detection rates in lesions classified as PI-RADS 4 and 5.

This review provides an in-depth examination of the efficacy and safety of finasteride and dutasteride, commonly used for treating benign prostatic hyperplasia and male androgenetic alopecia.

This review discusses the role of DHT in male sexual differentiation and fertility in individuals with 5α-reductase-2 deficiency, reporting no new clinical results.

This historical review traces the discovery of 5-alpha reductase inhibitors, widely used in urology, from the study of guevedoces, Dominican children with a rare disorder leading to significant androgenization at puberty.

This article reviews the role of 5α-reductase in androgen-related diseases like acne and androgenetic alopecia and reports no new clinical results, emphasizing the importance of studying the enzyme.

This article discusses the complexities of diagnosing hyperandrogenism in women and reviews potential treatments, such as antiandrogens and finasteride, but reports no new clinical findings.

MK-386 reduces sebum DHT levels.

This article reviews updates on 5 alpha-reductase inhibitors for treating male pattern hair loss and presents no new clinical findings; the author aims to enhance understanding of these therapies.

This study found that 1-year use of 5alpha-reductase inhibitors, dutasteride or finasteride, significantly lowered dihydrotestosterone levels without adversely affecting bone density, lipids, or hemoglobin in normal men.

This review summarizes recent advancements in steroidal 5α-reductase inhibitors for benign prostatic hyperplasia and reports no new clinical results.

This review highlights the challenges in screening for steroid 5 alpha-reductase inhibitors and discusses significant variability in the effectiveness of finasteride and dutasteride, calling for standardized testing methods to develop safer, more specific inhibitors from herbal preparations.

This study found that black cohosh extract BNO 1055 reduced testosterone-induced prostate and seminal vesicle growth in rats, suggesting it may contain potent 5α-reductase inhibitors useful for prostate cancer prevention.

This study examined the evolutionary and functional homology of steroid 5α-reductase and DET2 proteins, identifying protists as a common ancestor, and discovered a new subclass DET2-like in plants, potentially involved in polyprenol reduction.

This review discusses the role of steroid 5 alpha reductase 2 in converting testosterone to DHT and its association with conditions like benign prostatic hyperplasia and prostate cancer; it reports no new results.

This study found that a genetic variation in SRD5A2 influences the severity of PTSD symptoms in a sex-specific manner among traumatized African-American males.